Imvaq Therapeutics develops novel viral-based, armed immune-stimulating therapies using vaccinia and MVA platforms to treat a variety of solid tumors, including skin cancers, sarcoma, and triple-negative breast cancer. Its lead candidate, MQ710, is a second-generation armed Modified Vaccinia Ankara (MVA) viral immunotherapy. The company has a proprietary cGAS/STING screen to remove major immune-evasion and suppression genes in vaccinia and arms viruses with multiple immunostimulatory transgenes. Planned near-term development includes filing an IND and initiating Phase 1 clinical trials for MQ710, as well as advancing additional assets in its pipeline. Imvaq is pursuing both oncolytic vaccinia and non-oncolytic MVA strains for single-agent use and combinations with immune checkpoint inhibitors. Memorial Sloan Kettering Cancer Center researchers founded the company, and MSK holds institutional financial interests related to Imvaq via licensing agreements.

Total raised

$15M

Funding rounds

1

Latest round

Series B

Latest activity

Sep 2020